Rainbow Childrens Medicare (BOM:543524) Research & Development: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543524 Rainbow Childrens Medicare Ltd BOM:543524
90 GF Score
Price ₹1,537.60
GF Value ₹1,703.50
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Rainbow Childrens Medicare Research & Development?

Rainbow Childrens Medicare BOM:543524 -1.16% 90 Research & Development is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:543524 with a GF Score™ of 90/100 and a GF Value™ of ₹1,703.50 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Rainbow Childrens Medicare's Research & Development for the three months ended in Jun. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Rainbow Childrens Medicare  (BOM:543524) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Rainbow Childrens Medicare Research & Development Related Terms

Rainbow Childrens Medicare Research & Development Historical Data

* Premium members only.

The historical data trend for Rainbow Childrens Medicare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rainbow Childrens Medicare Research & Development Chart

Rainbow Childrens Medicare Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Rainbow Childrens Medicare Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:543524
90GF Score
Rainbow Childrens Medicare Ltd BOM:543524
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rainbow Childrens Medicare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Rainbow Childrens Medicare (BOM:543524) has a Research & Development of ₹0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Rainbow Childrens Medicare and its competitors.
Is Rainbow Childrens Medicare's Research & Development too high?
Rainbow Childrens Medicare's current Research & Development is ₹0 Mil. Overall, Rainbow Childrens Medicare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rainbow Childrens Medicare's Research & Development compare to HCA and THC?
Rainbow Childrens Medicare's Research & Development of ₹0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Rainbow Childrens Medicare and its competitors. Rainbow Childrens Medicare's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rainbow Childrens Medicare stock overvalued right now?
Based on GuruFocus' analysis, Rainbow Childrens Medicare (BOM:543524) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,703.50, compared to a current price of ₹1,537.60 — trading 9.7% below its estimated fair value. The current Research & Development is ₹0 Mil. Rainbow Childrens Medicare's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Rainbow Childrens Medicare (BOM:543524), the current Research & Development is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rainbow Childrens Medicare (BOM:543524) Overvalued in 2026?

Based on GuruFocus' analysis, Rainbow Childrens Medicare stock appears to be undervalued. The current stock price of ₹1,537.60 is trading 9.7% below its estimated GF Value™ of ₹1,703.50. GuruFocus considers Rainbow Childrens Medicare to be Modestly Undervalued.

Key valuation signals for BOM:543524:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹1,703.50 vs. price of ₹1,537.60 (9.7% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the BOM:543524 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rainbow Childrens Medicare Business Description

Other Exchanges RAINBOW:India
Address 8-2-19/1/A, Daulet Arcade, Karvy Lane, Road No. 11, Banjara Hills, Hyderabad, TG, IND, 500034
Rainbow Childrens Medicare Ltd operates a multi-specialty pediatric, obstetrics, and gynecology hospital chain in India. The company offers a wide range of services such as newborn and pediatric intensive care, pediatric multi-specialty services, pediatric quaternary care, obstetrics, and gynecology, which includes normal and complex obstetric care, and multidisciplinary fetal care, perinatal genetic and fertility care. Medical and Healthcare services have been considered the only reportable segment.
90GF Score

Get the complete analysis for BOM:543524

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,537.60
Price
₹1,703.50
GF Value